NASDAQ / LIVE COMPANY INTELLIGENCE

Imunon, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERIMNN
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / IMNN COVERAGE

What’s moving Imunon, Inc. now

Current reporting with the operating signal separated from the noise.

01
Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer

Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer

The story matters when it changes Imunon, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript

Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript

Investors are testing whether Imunon, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Imunon, Inc. Earnings Call Highlights Progress and Challenges

Imunon, Inc. Earnings Call Highlights Progress and Challenges

Investors are testing whether Imunon, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Imunon, Inc.: IMUNON Announces Reverse Stock Split

Imunon, Inc.: IMUNON Announces Reverse Stock Split

Investors are testing whether Imunon, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
Imunon, Inc. (IMNN) Q1 2025 Earnings Call Transcript

Imunon, Inc. (IMNN) Q1 2025 Earnings Call Transcript

Investors are testing whether Imunon, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
IMUNON, Inc. Initiates First Site for Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer, Announces ASCO Presentation

IMUNON, Inc. Initiates First Site for Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer, Announces ASCO Presentation

The story matters when it changes Imunon, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
07
IMUNON, Inc. Announces Phase 3 Trial for IMNN-001 Following Positive Phase 2 Survival Results in Advanced Ovarian Cancer

IMUNON, Inc. Announces Phase 3 Trial for IMNN-001 Following Positive Phase 2 Survival Results in Advanced Ovarian Cancer

The story matters when it changes Imunon, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest IMNN filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-12 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-13 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-31 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-30 · Period 2026-06-29SEC ↗8-KMaterial company eventFiled 2026-06-16 · Period 2026-06-16SEC ↗8-KMaterial company eventFiled 2026-06-04 · Period 2026-06-01SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-05-04 · Period 2026-05-04SEC ↗4Official SEC filingFiled 2026-07-21 · Period 2026-07-17SEC ↗
EARNINGS / QUARTERLY TRACKER

Imunon, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.